

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **NOTICE OF EXTRAORDINARY GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that an extraordinary general meeting (the “**EGM**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) will be held at 9th Floor, Block A2, Tianda Hi-Tech Park, No. 80, The 4th Avenue Teda, Tianjin, the People's Republic of China (the “**PRC**”) on Friday, 29 August 2025 at 10:00 a.m. to consider, if thought fit, passing the following resolutions as ordinary resolutions of the Company:

### **ORDINARY RESOLUTIONS**

To consider and approve the following resolutions as ordinary resolutions with or without amendments:

1 “**THAT,**

- (a) subject to the Stock Exchange of Hong Kong Limited granting the approval for the listing of, and permission to deal in, the H Shares which may fall to be issued and allotted pursuant to the vesting of the awarded shares to be granted under the share award scheme of the Company (the rules of which are contained in the document marked “A” produced to the EGM and signed by the chairman of the meeting for identification purposes) (the “**Share Award Scheme**”), the Share Award Scheme be and is hereby approved and adopted;

- (b) the directors of the Company be and are hereby authorised to do all such acts and to enter into all such transactions, arrangements and agreements as they may in their discretion consider necessary, desirable or expedient to give full effect to the Share Award Scheme, including but not limited to:
- (i) administering the Share Award Scheme and granting awarded shares to eligible participants thereunder;
  - (ii) allotting and issuing H Shares pursuant to the vesting of the awarded shares in accordance with the terms of the Share Award Scheme; and
  - (iii) making application to the Stock Exchange for the listing of, and permission to deal in, such H Shares to be issued and allotted pursuant to the Share Award Scheme; and
- (c) the Scheme Mandate Limit (as defined in the Share Award Scheme), being 10% of the number of H Shares in issue as at the date of passing of this resolution, be and is hereby approved.”

2. “**THAT,**

conditional upon the passing of resolution numbered 1, the sublimit (under the Scheme Mandate Limit (as defined in the Share Award Scheme)) on the total number of H Shares which may be issued in respect of all Awards (as defined in the Share Award Scheme) to be granted to Service Providers (as defined in the Share Award Scheme) under the Share Award Scheme and all the share options and share awards to be granted under any other Share Scheme(s) (as defined in the Share Award Scheme) of 30% of the Scheme Mandate Limit be and is hereby approved and adopted.”

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
12 August 2025

*Notes:*

1. Any shareholders of the Company entitled to attend and vote at the meeting mentioned above is entitled to appoint one or more proxies to attend and vote at the meeting on his, her or its behalf in accordance with the Articles of Association of the Company. A proxy needs not be a shareholder of the Company.
2. In order to be valid, the proxy form of the holder of the H Shares of the Company and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at Computershare Hong Kong Investor Services Limited of 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (the "**Company's Share Registrar**") not less than 24 hours before the time for holding the meeting or 24 hours before the time appointed for taking the poll.
3. In order to be valid, the proxy form of the holder of the Domestic Shares of the Company and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the registered address of the Company not less than 24 hours before the time for holding the meeting or 24 hours before the time appointed for taking the poll.
4. Shareholders of the Company or their proxies shall produce documents of their proof of identity when attending the meeting. Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. The register of the shareholders of the Company will be closed from 26 August 2025 to 29 August 2025 (both days inclusive), during which no transfer of shares will be registered. As regards holders of H Shares of the Company and in order to ascertain the entitlement to attendance at the above meeting, all properly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's Share Registrar not later than 4:30 p.m., 25 August 2025 for registration.
6. The registered address of the Company and the contact details of the Company are as follows:

No. 12 Tai Hua Road, The 5th Avenue, TEDA, Tianjin, the PRC

Fax No.: (8622) 5981 6909

*As at the date of this notice, the executive Directors of the Company is Sun Li; the nonexecutive Directors of the Company are He Xin, Li Ximing and Li Xueying; the independent nonexecutive Directors of the Company are Wang Yongkang, Gao Chun and Tu Xiangzhen.*

*This notice will remain on the GEM website at <http://www.hkgem.com> at the "Latest Company Announcements" page for 7 days from the date of its posting. This notice will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*